Evidence that neuropeptide Y is present in gabaergic neurons in the superficial dorsal horn of the rat spinal cord

doi:10.1016/0306-4522(93)90218-5

Neuroscience

Volume 53, Issue 2, March 1993, Pages 537-545

https://doi.org/10.1016/0306-4522(93)90218-5 Get rights and content

Abstract

In order to determine whether or not neuropeptide Y coexists with GABA or glycine in rat dorsal horn, we have examined 84 neuropeptide Y-immunoreactive neurons in laminae I–III with a combined pre- and postembedding immunocytochemical method. All of the neuropeptide Y-immunoreactive neurons were also GABA-immunoreactive, but they were either non-immunoreactive or weakly immunoreactive with the glycine antiserum. In addition, a double-label immunofluoresence method was used to search for co-localization of neuropeptide Y and [Met]enkephalin in spinal cord. Although the two types of peptide immunoreactivity often coexisted in varicosities around the central canal and in the ventral horn, such coexistence was not seen in the superficial dorsal horn.

These results suggest that neuropeptide Y is present in GABAergic neurons in laminae I–III of rat dorsal horn, but that it is largely or completely restricted to those neurons which do not contain glycine. In addition, the cells that contain GABA and neuropeptide Y appear to form a different population from those that contain GABA and [Met]enkephalin. Neuropeptide Y administered by intrathecal injection causes analgesia, and there is evidence that this may involve a presynaptic mechanism.

The results of the present study suggest that neuropeptide Y may act in conjunction with GABA to produce presynaptic inhibition of nociceptive primary afferents.

References (44)

AllenJ.M. et al.
Neuropeptide Y in human spinal cord
Brain Res.
(1984)
BarberR.P. et al.
GABAergic terminals are presynaptic to primary afferent terminals in the substantia gelatinosa of the rat spinal cord
Brain Res.
(1978)
BlessingW.W. et al.
Neuropeptide Y-like immunoreactive CA₁ neurones in the rostral ventrolateral medulla of the rabbit project to sympathetic preganglionic neurones in the spinal cord
J. auton. nerv. Syst.
(1987)
ColmersW.F. et al.
Neuropeptide Y reduces orthodromically evoked population spike in rat hippocampal CA₁ by a possibly presynaptic mechanism
Brain Res.
(1985)
DeQuidtM.E. et al.
Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system—II. Immunohistochemical analysis
Neuroscience
(1986)
DugganA.W. et al.
Microinjection of neuropeptide Y into the superficial dorsal horn reduces stimulus-evoked release of immunoreactive substance P in the anesthetized cat
Neuroscience
(1991)
EmsonP.C. et al.
NPY-a new member of the pancreatic polypeptide family
Trends Neurosci.
(1984)
HökfeltT. et al.
Avian pancreatic polypeptide (APP) immunoreactive neurons in the spinal cord and trigeminal nucleus
Peptides
(1981)
HoletsV.R. et al.
Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their different projections to the spinal cord, cerebral cortex and hypothalamus
Neuroscience
(1988)
HuntS.P. et al.
Presence of avian panereatic polypeptide-like immunoreactivity in catecholamine and methionine-enkephalin-containing neurones within the central nervous system
Neurosci. Lett.
(1981)

HuntS.P. et al.

An immunohistochemical study of neuronal populations containing neuropeptides or γ-aminobutyrate within the superficial layers of the rat dorsal horn

Neuroscience

(1981)

JonesE.G. et al.

Co-localization of GABA and neuropeptides in neocortical neurons

Trends Neurosci.

(1986)

KarS. et al.

Quantitative autoradiographic localization of [¹²⁵I]neuropeptide Y receptor binding sites in rat spinal cord and the effects of neonatal capsaicin, dorsal rhizotomy and peripheral axotomy

Brain Res.

(1992)

KrukoffT.L.

Neuropeptide Y-like immunoreactivity in cat spinal cord with special reference to autonomic areas

Brain Res.

(1987)

LevyR.A.

The role of GABA in primary afferent depolarization

Prog. Neurobiol.

(1977)

MaxwellD.J. et al.

Central boutons of glomeruli in the spinal cord of the cat are enriched with l-glutamate-like immunoreactivity

Neuroscience

(1990)

RoddyD.R. et al.

Distribution of neuropeptide Y in the spinal cords of cat, dog, rat, man and pig

Regul. Pept.

(1990)

ToddA.J.

Immunohistochemical evidence that acetylcholine and glycine exist in different populations of GABAergic neurons in lamina III of rat spinal dorsal horn

Neuroscience

(1991)

ToddA.J. et al.

GABA-like immunoreactivity in type I glomeruli of rat substantia gelatinosa

Brain Res.

(1990)

ToddA.J. et al.

GABA-immunoreactive neurones in the dorsal horn of the rat spinal cord

Neuroscience

(1989)

ToddA.J. et al.

Immunocytochemical evidence that GABA and neurotensin exist in different neurons in laminae II and III of rat spinal dorsal horn

Neuroscience

(1992)

ToddA.J. et al.

Co-localization of met-enkephalin and somatostatin in the spinal cord of the rat

Neurosci. Lett.

(1992)

Cited by (96)

5.12 - Functional Populations Among Interneurons in the Dorsal Horn
2020, The Senses: A Comprehensive Reference: Volume 1-7, Second Edition
The superficial dorsal horn of the spinal cord receives input from primary sensory neurons conveying information that is perceived as pain and itch. The vast majority of neurons in this area are interneurons, which form circuits that are essential for the behavioral expression of these percepts. The classes of neuron involved in these circuits and their functions are poorly understood, although recent studies have developed categorization schemes that account for most of these cells. This chapter highlights the important methodologies for identifying interneuron populations in the dorsal horn and discusses these populations in the light of their predicted functions.
The Neuropeptide Y System Regulates Both Mechanical and Histaminergic Itch
2018, Journal of Investigative Dermatology
Itch is a somatosensory modality that serves to alert an organism to harmful elements removable by scratching, such as parasites and chemical irritants. Recently, ablation or silencing of neuropeptide Y (NPY)-expressing spinal interneurons was reported to selectively enhance mechanical itch, whereas chemical itch was unaffected. We examined the effect of activating the NPY/Y₁ receptor system on scratch behavior in mice. We found that intrathecal administration of the Y₁ agonist [Leu³¹,Pro³⁴]-NPY (LP-NPY) attenuated itch behavior induced by application of 0.07 g von Frey filament in the nape of the neck compared with saline treatment, indicating that activation of the spinal NPY/Y₁ system dampens mechanical itch. However, intrathecal administration of LP-NPY also attenuated chemically induced scratching provoked by intradermal application of histamine or the mast cell degranulator 48/80 (histaminergic itch), and the latter effect could be reversed by administration of the Y₁ antagonist BIBO3304. Intrathecal application of the native nonselective agonist NPY also attenuated histamine or 48/80-induced scratching. Our analyses emphasize the importance of including additional quantitative parameters to characterize the full spectrum of itch behavior and show that the NPY/Y₁ system dampens both mechanically and chemically induced scratching and hence is shared by the two submodalities of itch.
The histology, physiology, neurochemistry and circuitry of the substantia gelatinosa Rolandi (lamina II) in mammalian spinal cord
2018, Progress in Neurobiology
The substantia gelatinosa Rolandi (SGR) was first described about two centuries ago. In the following decades an enormous amount of information has permitted us to understand - at least in part - its role in the initial processing of pain and itch.
Here, I will first provide a comprehensive picture of the histology, physiology, and neurochemistry of the normal SGR. Then, I will analytically discuss the SGR circuits that have been directly demonstrated or deductively envisaged in the course of the intensive research on this area of the spinal cord, with particular emphasis on the pathways connecting the primary afferent fibers and the intrinsic neurons. The perspective existence of neurochemically-defined sets of primary afferent neurons giving rise to these circuits will be also discussed, with the proposition that a cross-talk between different subsets of peptidergic fibers may be the structural and functional substrate of additional gating mechanisms in SGR. Finally, I highlight the role played by slow acting high molecular weight modulators in these gating mechanisms.
A quantitative study of neurochemically defined populations of inhibitory interneurons in the superficial dorsal horn of the mouse spinal cord
2017, Neuroscience
Citation Excerpt :
The other channels were then viewed and the expression of PPD, NPY and/or sst2A in each selected neuron was recorded. It has been reported that all NPY-immunoreactive neurons in laminae I–III of the rat dorsal horn are also GABA-immunoreactive, and are therefore inhibitory interneurons (Rowan et al., 1993). To test whether this is also the case in the mouse we immunostained sections from the L4 segments of three mice to reveal NPY and the transcription factor Pax2.
Around a quarter of neurons in laminae I–II of the dorsal horn are inhibitory interneurons. These play an important role in modulating somatosensory information, including that perceived as pain or itch. Previous studies in rat identified four largely non-overlapping neurochemical populations among these cells, defined by expression of galanin, neuropeptide Y (NPY), neuronal nitric oxide synthase (nNOS) or parvalbumin. The galanin cells were subsequently shown to coexpress dynorphin. Several recent studies have used genetically modified mice to investigate the function of different interneuron populations, and it is therefore important to determine whether the same pattern applies in mouse, and to estimate the relative sizes of these populations. We show that the neurochemical organization of inhibitory interneurons in mouse superficial dorsal horn is similar to that in the rat, although a larger proportion of these neurons (33%) express NPY. Between them, these four populations account for ∼75% of inhibitory cells in laminae I–II. Since ∼25% of inhibitory interneurons in this region belong to a novel calretinin-expressing type, our results suggest that virtually all inhibitory interneurons in superficial dorsal horn can be assigned to one of these five neurochemical populations. Although our main focus was inhibitory neurons, we also identified a population of excitatory dynorphin-expressing cells in laminae I–II that are largely restricted to the medial part of the mid-lumbar dorsal horn, corresponding to glabrous skin territory. These findings are important for interpretation of studies using molecular-genetic techniques to manipulate the functions of interneuron populations to investigate their roles in somatosensory processing.
Spinal neuropeptide expression and neuropathic behavior in the acute and chronic phases after spinal cord injury: Effects of progesterone administration
2017, Peptides
Patients with spinal cord injury (SCI) develop chronic pain that severely compromises their quality of life. We have previously reported that progesterone (PG), a neuroprotective steroid, could offer a promising therapeutic strategy for neuropathic pain. In the present study, we explored temporal changes in the expression of the neuropeptides galanin and tyrosine (NPY) and their receptors (GalR1 and GalR2; Y1R and Y2R, respectively) in the injured spinal cord and evaluated the impact of PG administration on both neuropeptide systems and neuropathic behavior. Male rats were subjected to spinal cord hemisection at T13 level, received daily subcutaneous injections of PG or vehicle, and were evaluated for signs of mechanical and thermal allodynia. Real time PCR was used to determine relative mRNA levels of neuropeptides and receptors, both in the acute (1 day) and chronic (28 days) phases after injury. A significant increase in Y1R and Y2R expression, as well as a significant downregulation in GalR2 mRNA levels, was observed 1 day after SCI. Interestingly, PG early treatment prevented Y1R upregulation and resulted in lower NPY, Y2R and GalR1 mRNA levels. In the chronic phase, injured rats showed well-established mechanical and cold allodynia and significant increases in galanin, NPY, GalR1 and Y1R mRNAs, while maintaining reduced GalR2 expression. Animals receiving PG treatment showed basal expression levels of galanin, NPY, GalR1 and Y1R, and reduced Y2R mRNA levels. Also, and in line with previously published observations, PG-treated animals did not develop mechanical allodynia and showed reduced sensitivity to cold stimulation. Altogether, we show that SCI leads to considerable changes in the spinal expression of galanin, NPY and their associated receptors, and that early and sustained PG administration prevents them. Moreover, our data suggest the participation of galaninergic and NPYergic systems in the plastic changes associated with SCI-induced neuropathic pain, and further supports the therapeutic potential of PG- or neuropeptide-based therapies to prevent and/or treat chronic pain after central injuries.
Rebuilding CNS inhibitory circuits to control chronic neuropathic pain and itch
2017, Progress in Brain Research
Cell transplantation offers an attractive alternative to pharmacotherapy for the management of a host of clinical conditions. Most importantly, the transplanted cells provide a continuous, local delivery of therapeutic compounds, which avoids many of the adverse side effects associated with systemically administered drugs. Here, we describe the broad therapeutic utility of transplanting precursors of cortical inhibitory interneurons derived from the embryonic medial ganglionic eminence (MGE), in a variety of chronic pain and itch models in the mouse. Despite the cortical environment in which the MGE cells normally develop, these cells survive transplantation and will even integrate into the circuitry of an adult host spinal cord. When transplanted into the spinal cord, the cells significantly reduce the hyperexcitability that characterizes both chronic neuropathic pain and itch conditions. This MGE cell-based strategy differs considerably from traditional pharmacological treatments as the approach is potentially disease modifying (i.e., the therapy targets the underlying etiology of the pain and itch pathophysiology).

View all citing articles on Scopus

View full text

Evidence that neuropeptide Y is present in gabaergic neurons in the superficial dorsal horn of the rat spinal cord

Abstract

Brain Res.

Brain Res.

J. auton. nerv. Syst.

Brain Res.

Neuroscience

Neuroscience

Trends Neurosci.

Peptides

Neuroscience

Neurosci. Lett.

Neuroscience

Trends Neurosci.

Brain Res.

Brain Res.

Prog. Neurobiol.

Neuroscience

Regul. Pept.

Neuroscience

Brain Res.

Neuroscience

Neuroscience

Neurosci. Lett.